Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.

about

Deciphering Key Pharmacological Pathways of Qingdai Acting on Chronic Myeloid Leukemia Using a Network Pharmacology-Based Strategy

P2860

Q58777160-C5E37304-624C-4AC0-95F3-00408FAAE001

P2860

Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.

Item

http://www.wikidata.org/entity/Q48189225

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Inadequate response to imatini ...... ug interaction with phenytoin.

@en

Inadequate response to imatini ...... ug interaction with phenytoin.

@nl

type

Item

label

Inadequate response to imatini ...... ug interaction with phenytoin.

@en

Inadequate response to imatini ...... ug interaction with phenytoin.

@nl

prefLabel

Inadequate response to imatini ...... ug interaction with phenytoin.

@en

Inadequate response to imatini ...... ug interaction with phenytoin.

@nl

P1476

Inadequate response to imatini ...... rug interaction with phenytoin

@en

P2093

E González-Arias

http://www.w3.org/2001/XMLSchema#string

I Gómez-Centurión

http://www.w3.org/2001/XMLSchema#string

J L Díez

http://www.w3.org/2001/XMLSchema#string

S Osorio

http://www.w3.org/2001/XMLSchema#string

P2860

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.

Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method

Chronic Myelogenous Leukemia, Version 1.2014

Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension.

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.

A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Drug-drug interactions with imatinib: An observational study.

Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.

P304

694-698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155217743565

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Xandra García-González

V Escudero-Vilaplana

P577

2017-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29199506

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.

about

P2860

P2860

Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921